Premier Stocks League

NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff? 🔗

Novartis said on Friday that its late-stage trial of pelacarsen failed to reduce the risk of cardiovascular events.

Dividend Champion, Contender, And Challenger Highlights: Week September 6 🔗

Explore this week’s dividend updates for Dividend Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend and pay...

Which dow jones stocks are moving on Friday? 🔗

Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.

Amgen (AMGN) Says Repatha Reduced Mortality Before a First Heart Attack or Stroke. Can Earlier Use Expand the Market? 🔗

Amgen Inc. (NASDAQ:AMGN) reported that Repatha reduced the risk of all-cause mortality by 20% in a prespecified secondary analysis of the Phase 3 VESA...

AMGN's MariTide: Can Convenience Drive its Obesity Market Share? 🔗

Amgen's MariTide could target obesity with less frequent dosing, offering a convenience edge as competition from Lilly and Novo Nordisk intensifi...

1 Healthcare Stock for Long-Term Investors and 2 We Ignore 🔗

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry ...

Discover which dow jones stocks are making waves on Thursday. 🔗

Stay informed about the performance of the dow jones index one hour before the close of the markets on Thursday. Uncover the top gainers and losers in...

Why Is Amgen (AMGN) Up 8.6% Since Last Earnings Report? 🔗

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Dogs Of The Dow: No Buys And Few Worth Watching 🔗

Dogs of the Dow look overvalued, with no must-buy dividend signals.

Is Amgen (AMGN) Reasonable Or Rich As Cash Flow Improves? 🔗

Amgen stock has logged a strong 5 year run, yet current valuation checks send mixed signals as the intrinsic value estimate suggests a discount while ...

TEZSPIRE’s Positive EoE Phase 3 Results Could Be A Game Changer For Amgen (AMGN) 🔗

Amgen and AstraZeneca recently reported positive Phase 3 CROSSING results showing TEZSPIRE improved histologic remission and dysphagia symptoms in pat...

AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE 🔗

Amgen (NASDAQ: AMGN) will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m. ET on Thursday, September 10, 2026. Thomas Dittrich, exe...

Amgen Stock Signals Its Confidence. The Market Agrees. 🔗

The real bet is on what lies beyond this year's performance: a pipeline that could change everything.

Which dow jones stocks are moving on Wednesday? 🔗

Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Wednesday as we examine the latest happenings i...

Rare-Disease Drug Tavneos Faces UK Withdrawal 🔗

CSL Vifor holds the U.K. authorization and is leading regulator talks

J&J Faces Multiple Headwinds: Can the Healthcare Giant Sustain Growth? 🔗

JNJ faces Stelara and upcoming drug LOEs, MedTech weakness and talc litigation, but targets accelerated growth in 2026 and beyond.

2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB 🔗

Complement Inhibitors Market Complement Inhibitors Market Dublin, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The "Complement Inhibitors Market (2nd Editi...

Heart-Drug Breakthroughs Can’t Stop Biotech Stocks From Sliding 🔗

Impressive results came out on drugs from Amgen, Arrowhead Pharmaceuticals, and Crispr Therapeutics. Their shares are all lower this week.

Stay informed with the top movers within the dow jones index on Tuesday. 🔗

Get insights into the dow jones index performance on Tuesday. Explore the top gainers and losers within the dow jones index in today's session.

Stocks rise for first time in four sessions as Treasury yields take breather: Live updates 🔗

Stocks rose on Wednesday as U.S. Treasury yields took a breather from the recent run-up that sent them to multiyear highs.

These dow jones stocks are moving in today's session 🔗

Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Tue...

Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly’s GLP-1 Drugs 🔗

Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most...

Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer 🔗

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medic...

One Of Amgen's Biggest Moneymakers Cuts The Risk Of Dying By 20% 🔗

Amgen said Monday its cholesterol buster, Repatha, reduced the risk of death by 20% in a study of more than 12,000 high-risk patients.

Aging Population Drives Healthcare Growth: Stocks to Watch 🔗

AbbVie, Tandem Diabetes Care and Amgen are targeting aging-related healthcare growth through advances in immunology, diabetes and cardiovascular care.

Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know 🔗

How Is Amgen’s Stock Performance Compared to Other General Drug Manufacturers 🔗

AMGN has outperformed the broader market over the past year, while analysts remain moderately bullish on its future prospects.

Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs 🔗

Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more a...

Non-Melanoma Skin Cancer Market: Focus on Disease Indication, Treatment Type, Country and Region, 2025-2035 🔗

The global non-melanoma skin cancer (NMSC) market is growing as basal cell carcinoma and squamous cell carcinoma rates rise due to UV exposure and agi...

Palmoplantar Pustulosis Market Report Now Available — Profiles AbbVie, Johnson & Johnson, Novartis, Amgen, UCB, and 4 Other Key Players, Segmented by Treatment Type and Distribution Channel 🔗

The global palmoplantar pustulosis market is expanding as awareness, diagnosis rates and demand for targeted biologic therapies increase. Advances in ...

Cramer’s Stop Trading: Amgen 🔗

CNBC’s Jim Cramer explains why he is keeping an eye on shares of Amgen.